Adicet Bio Inc
ACET
Market Cap$59.94M
Close$
$0.45
37.4% downside
Current Fair Value
37.4% downsideOvervalued by 37.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $59.94 Million |
|---|---|
| Enterprise Value | $40.58 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.33 |
| Beta | 1.61 |
| Outstanding Shares | 91,085,506 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.55 |
|---|---|
| PEG | -12.56 |
| Price to Sales | - |
| Price to Book Ratio | 0.71 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.33 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.38 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Adicet Bio, Inc.
152 employees
CEO: Mr. Chen Schor BA, CPA, M.B.A. Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell recepto...